Offerings Archives - Page 58 of 166

1 minute read

Brainstorm Cell Therapeutics Announces Pricing Of $7.5M Registered Direct Offering For The Purchase And Sale Of 4,054,055 Shares Of Common Stock And Warrants At A Price Of $1.85/Share, Warrants Will Have An Excersize Price Of $2/Share

July 17, 9:16 AM

BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) (the "Company"), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it has entered into a securities

BCLI

1 minute read

Janux Therapeutics Announces Pricing Of $60M Underwritten Offering Of 4,153,717 Shares Of Common Stock And Pre-Funded Warrants To Purchase 583,483 Shares At A Price Of $12.46/Share

By Happy Mohamed

July 17, 8:46 AM

Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell

JANX

1 minute read

1847 Holdings LLC Announces Pricing Of ~$2.5M Registered Direct Offering With Certain Institutional Investors To Purchase An Aggregate Of 10,416,667 Shares And/Or Pre-Funded Warrants To Purchase Shares Of The Company, At A Purchase Price Of $0.24/Share

By Happy Mohamed

July 14, 11:52 AM

1847 Holdings LLC (NYSE:EFSH) ("1847 Holdings" or the "Company"), a unique holding company that combines the attractive attributes of owning private, lower-middle market businesses with the

EFSH

1 minute read

Galmed Pharmaceuticals Announces Pricing Of $7M Public Offering Of 5.6M Shares And Warrants At A Purchase Price Of $1.25/Share

By Happy Mohamed

July 14, 9:31 AM

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic diseases, announced today that it has entered into

GLMD

2 minute read

Caribou Biosciences Raises $125M Via Equity Just One Week After Pfizer Invested $25M

By Vandana Singh

July 14, 9:27 AM

Caribou Biosciences Inc (NASDAQ: CRBU) reported long-term follow-up data from the dose escalation portion of the ongoing ANTLER Phase 1 trial of CB-010, an allogeneic anti-CD19 CAR-T cell therapy for relapsed or refractory B cell

CRBU

1 minute read

Molecular Templates Announces Up to $40M Private Placement Offering

By Benzinga Newsdesk

July 13, 8:16 AM

Molecular Templates, Inc. (NASDAQ:MTEM, ", Molecular Templates, ", or ", MTEM", )))), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted

MTEM

1 minute read

ShiftPixy Plunges After $3.1M Equity Offering

By Shivani Kumaresan

July 12, 8:55 AM

ShiftPixy Inc (NASDAQ:PIXY) has priced its public offering of 2.06 million units at $1.50 per unit. Each unit consists of…

PIXY

1 minute read

Designer Brands Inc. Announces Final Results of Modified Dutch Auction Tender Offer

By Benzinga Newsdesk

July 12, 8:51 AM

Based on the final count by Computershare Trust Company, N.A., the depositary for the tender offer (the "Depositary"), a total of 1,470,832 shares of the Company's Class A Common Shares, without par value (each, a

DBI

1 minute read

Why Iovance Biotherapeutics Shares Are Tumbling Tuesday

By Adam Eckert

July 11, 9:30 AM

Iovance Biotherapeutics Inc (NASDAQ: IOVA) shares are trading lower Tuesday after the company announced the pricing of a public o

IOVA

1 minute read

BioRestorative Therapies Announces Secondary Stock Offering Of $0.7M At $3.03/Share

By Benzinga Newsdesk

July 11, 8:33 AM

BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced it has entered into a

BRTX